2022-502456-31-00招募中1 期
A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Incyte Corp.
- 入组人数
- 75
- 试验地点
- 15
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Information
Scientific
Incyte Corp.
研究点 (15)
Loading locations...
相似试验
招募中
1 期
A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid TumorsAdvanced or metastatic solid tumorsCTIS2022-502456-31-00Incyte Corp.165
招募中
1 期
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsJPRN-jRCT2031230426eda Eiji225
已完成
不适用
A Phase 1, Open-Label, multicenter Study of INCA00186 as monotherapy or in combination with immunotherapy in participants with advanced solid tumorsAdvanced Solid Tumors10027656NL-OMON53794Incyte Corporation35
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparingthe Efficacy and Safety of a Sitagliptin-Based Treatment Paradigmto a Liraglutide-Based Treatment Paradigm in PatientsWith Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control onMetformin Monotherapy - NDPatients with T2DM andinadequate glycemic control (A1C =7.0% and =11.0%) on metformin monotherapyMedDRA version: 9.1Level: LLTClassification code 10053247EUCTR2010-023759-27-ITMERCK SHARP & DOHME CORP.600
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin MonotherapyEUCTR2010-023759-27-LTMerck Sharp & Dohme Corp.600